Navigation Links
ULURU Inc. Raises $140,000 in Convertible Debt Offering
Date:6/14/2011

ADDISON, Texas, June 14, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has completed a $140,000 convertible debt financing with Kerry P. Gray, the Company's Chairman, President, and Chief Executive Officer. The Company intends to use the funds for general corporate purposes.

The convertible notes will bear interest at the rate of 10.0% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on June 13, 2014. The outstanding principal balance of the notes may be converted into shares of ULURU Inc. common stock, at the option of the note holder and at any time, at a conversion price of $0.08 per share or 1,750,000 shares of common stock. The company may force conversion of the convertible note if the common stock trades for a defined period of time at a price greater than $0.12. The convertible note is secured by the grant of a security interest in the inventory, accounts receivables and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.

As part of the convertible debt financing, Mr. Gray will also receive a warrant to purchase up to 525,000 shares of ULURU Inc.'s common stock. The warrant has an exercise price of $0.08 per share and is exercisable at any time until June 13, 2016.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the anticipated closing of the transaction and the Company's products. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's lack of profitability, the sufficiency of ULURU's working capital, the need for additional capital to operate its business, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Denmark , March 23, 2017 Ascendis ... its innovative TransCon technology to address significant unmet medical ... will host a conference call and webcast on Monday, ... the Endocrine Society in Orlando, Florida ... disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and ...
(Date:3/23/2017)... 2017  Cornerstone Pharmaceuticals, Inc., a clinical-stage, ... today.  Following successful End-of-Phase I (EOP1) Type ... Drug Administration (FDA), the Company has been ... forward to conduct pivotal trials of its ... myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... AVIV, Israel , March 23, 2017 ... on oncology and immunology, announced today that it has acquired ... immunotherapy platform. Acquisition consideration consisted of a $6 million upfront ... remainder in BioLineRx shares. Additional future payments may be made ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... Benefits delivery trailblazer, Hodges-Mace, LLC, ... centralized benefits dashboard solving one of the top frustrations in employee benefits – ... first time, employees can access up-to-date information and account balances for all of ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... 23, 2017 , ... ChenMed, a privately owned medical, management ... strategic executive team expansion needed to further optimize growth and performance. , “We ... Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and Donald Trexler ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access ... As experts in dangerous situations the Inflow IQ team can help people. Get ... clean & refreshing knowledge systems that enhance life. , Authentically enjoy ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March 2017, ... US Special Operations Command’s Patriot Award. The award was presented by the USSOCOM ... Dagger Foundation for its significant and enduring support to the command. , ...
Breaking Medicine News(10 mins):